Prognostic role of E-cadherin and Vimentin expression in various subtypes of soft tissue leiomyosarcomas

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Tian, Wei ^a   Wang, Guowen ^a   Yang, Jilong ^a   Pan, Yi ^a   Ma, Yulin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

E cadherin; Epithelial differentiation; Leiomyosarcoma; Vimentin

Indexed keywords

UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CELL DIFFERENTIATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LEIOMYOSARCOMA; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84871717606     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0401-y     Document Type: Article

References (26)

1. Danielson LS, Menendez S, Attolini CS, et al. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010;177:908-17.
2. Svarvar C, Bohling T, Berlin O, et al. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer. 2007;109:282-91.
3. Yang J, Eddy JA, Pan Y, et al. Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol Cell Proteomics. 2010;9:2405-13.
4. Gogou PN, Batistatou A, Pakos EE, et al. Expression of E-cadherin, beta-catenin and topoisomerase IIalpha in leiomyosarcomas. Clin Transl Oncol. 2009;11:548-51.
5. Fougner SL, Lekva T, Borota OC, et al. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95:2334-42.
6. Beck AH, Lee CH, Witten DM, et al. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene. 2010;29:845-54.
7. Toyoshima M, Okamura C, Niikura H, et al. Epithelioid leiomyosarcoma of the uterine cervix: a case report and review of the literature. Gynecol Oncol. 2005;97:957-60.
8. Nicolas MM, Tamboli P, Gomez JA, et al. Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases. Hum Pathol. 2010;41:663-71.
9. Suster S. Epithelioid leiomyosarcoma of the skin and subcutaneous tissue. Clinicopathologic, immunohistochemical, and ultrastructural study of five cases. Am J Surg Pathol. 1994;18:232-40.
10. Tsiatis AC, Herceg ME, Keedy VL, et al. Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Mod Pathol. 2009;22:1432-8.
11. Murphey MD. World Health Organization classification of bone and soft tissue tumors: modifications and implications for radiologists. Semin Musculoskelet Radiol. 2007;11:201-14.
12. Liu LK, Jiang XY, Zhou XX, et al. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol. 2010;23:213-24.
13. Koo JS, Jung W, Jeong J. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast cancer. Jpn J Clin Oncol. 2009;39:560-8.
14. Ansenberger K, Zhuge Y, Lagman JA, et al. E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer. Gynecol Oncol. 2009;113:362-9.
15. Huiping C, Kristjansdottir S, Jonasson JG, et al. Alterations of E-cadherin and beta-catenin in gastric cancer. BMC Cancer. 2001;1:16.
16. Theys J, Jutten B, Habets R, et al. E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 2011;99:392-7.
17. Marijon H, Dokmak S, Paradis V, et al. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol. 2011;54:1073-8.
18. Hu X, Ruan Y, Cheng F, et al. p130Cas, E-cadherin and beta-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol. 2011;18:630-7.
19. Nijkamp MM, Span PN, Hoogsteen IJ, et al. Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol. 2011;99:344-8.
20. Bosch FX, Andl C, Abel U, et al. E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. Int J Cancer. 2005;114:779-90.
21. Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:253-60.
22. Tang B, Peng ZH, Yu PW, et al. Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes. Med Oncol. 2011;28:502-8.
23. Kaur G, Carnelio S, Rao N, et al. Expression of E-cadherin in primary oral squamous cell carcinoma and metastatic lymph nodes: an immunohistochemical study. Indian J Dent Res. 2009;20:71-6.
24. Al-Saad S, Al-Shibli K, Donnem T, et al. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer. 2008;99:1476-83.
25. Hu J, Shao S, Song Y, et al. Hepatocyte growth factor induces invasion and migration of ovarian cancer cells by decreasing the expression of E-cadherin, beta-catenin, and caveolin-1. Anat Rec (Hoboken). 2010;293:1134-9.
26. Cagle LA, Mirra JM, Storm FK, et al. Histologic features relating to prognosis in synovial sarcoma. Cancer. 1987;59:1810-4.